Customize your JAMA Network experience by selecting one or more topics from the list below.
Borroni B, Colciaghi F, Caltagirone C, et al. Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type: A 2-Year Follow-up Study. Arch Neurol. 2003;60(12):1740–1744. doi:10.1001/archneur.60.12.1740
Alteration of the amyloid precursor protein (APP) forms ratio has been described in the platelets of patients with dementia of Alzheimer type (DAT) and in a subset of subjects with mild cognitive impairment (MCI).
To evaluate the potential role of the platelet APP forms ratio in predicting progression from MCI to DAT.
Thirty subjects with MCI underwent a clinical and neuropsychological examination and a determination of the platelet APP forms ratio. Subjects were followed up periodically for 2 years, and the progression to dementia was evaluated.
Community population-based sample of patients admitted for memory complaints.
Patients who progressed to DAT at the 2-year follow-up (n = 12) showed a significant decrease of baseline platelet APP forms ratio values (mean ± SD, 0.36 ± 0.28) compared with stable MCI subjects (mean ± SD, 0.73 ± 0.32) (P<.01) and patients who developed other types of dementia (mean ± SD, 0.83 ± 0.27) (P = .03). By fixing a cutoff score of 0.6, 10 (83%) of the 12 DAT patients showed baseline values below the cutoff, whereas 10 (71%) of 14 subjects who either developed non-Alzheimer–type dementia or maintained cognitive functions had values in the normal range.
Mild cognitive impairment is a major risk factor for DAT, and Alzheimer disease–related pathological changes can be identified in patients converting to DAT within a 2-year follow-up.
Create a personal account or sign in to: